La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
ReShape Lifesciences Croissance future
Future contrôle des critères 2/6
ReShape Lifesciences is forecast to grow earnings and revenue by 46.8% and 26.1% per annum respectively while EPS is expected to grow by 68.2% per annum.
Informations clés
46.8%
Taux de croissance des bénéfices
68.2%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 15.9% |
| Taux de croissance des recettes | 26.1% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | n/a |
Mises à jour récentes de la croissance future
Recent updates
Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2024 | 19 | -19 | N/A | N/A | 1 |
| 12/31/2023 | 16 | -19 | N/A | N/A | 2 |
| 12/31/2022 | 11 | -35 | N/A | N/A | 2 |
| 9/30/2022 | 11 | -65 | -23 | -22 | N/A |
| 6/30/2022 | 12 | -71 | -25 | -25 | N/A |
| 3/31/2022 | 13 | -65 | -21 | -21 | N/A |
| 12/31/2021 | 14 | -62 | -16 | -15 | N/A |
| 9/30/2021 | 14 | -35 | -14 | -14 | N/A |
| 6/30/2021 | 14 | -22 | -7 | -7 | N/A |
| 3/31/2021 | 12 | -22 | -8 | -7 | N/A |
| 12/31/2020 | 11 | -22 | -9 | -9 | N/A |
| 9/30/2020 | 12 | -38 | -8 | -8 | N/A |
| 6/30/2020 | 12 | -62 | -12 | -11 | N/A |
| 3/31/2020 | 15 | -74 | -12 | -12 | N/A |
| 12/31/2019 | 15 | -74 | -14 | -14 | N/A |
| 9/30/2019 | 11 | -52 | -20 | -20 | N/A |
| 6/30/2019 | 8 | -28 | -20 | -20 | N/A |
| 3/31/2019 | 4 | -35 | -24 | -24 | N/A |
| 12/31/2018 | 1 | -38 | -28 | -27 | N/A |
| 9/30/2018 | 0 | -42 | -29 | -29 | N/A |
| 6/30/2018 | 1 | -47 | -30 | -30 | N/A |
| 3/31/2018 | 1 | -30 | -30 | -29 | N/A |
| 12/31/2017 | 1 | -30 | -25 | -25 | N/A |
| 9/30/2017 | 1 | -29 | -19 | -19 | N/A |
| 6/30/2017 | 1 | -25 | -18 | -18 | N/A |
| 3/31/2017 | 1 | -23 | -18 | -18 | N/A |
| 12/31/2016 | 1 | -23 | -21 | -21 | N/A |
| 9/30/2016 | 1 | -26 | -23 | -22 | N/A |
| 6/30/2016 | 1 | -23 | N/A | -24 | N/A |
| 3/31/2016 | 0 | -26 | N/A | -24 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 24O is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: 24O is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: 24O is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: 24O's revenue (26.1% per year) is forecast to grow faster than the German market (4.6% per year).
Croissance élevée des revenus: 24O's revenue (26.1% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if 24O's Return on Equity is forecast to be high in 3 years time